Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications

BJU International

Volumn 111, Issue 5, 2013, Pages 745-752

  Shao, Yu Hsuan ^a,b   Moore, Dirk F ^a,c   Shih, Weichung ^a,c   Lin, Yong ^a,c   Jang, Thomas L ^a   Lu Yao, Grace L ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ADT; baseline risk; fracture; prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; FRACTURES, BONE; HUMANS; INCIDENCE; MALE; ORCHIECTOMY; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 84876295996     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11758.x     Document Type: Article

References (22)

1. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-181
2. Shahinian VB, Kuo Y-F, Gilbert SM,. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010; 363: 1822-1832
3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164
4. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J,. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-139
5. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL,. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903
6. Dickman PW, Adolfsson J, Astrom K, Steineck G,. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004; 172: 2208-2212
7. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-3458
8. Wadhwa VK, Weston R, Mistry R, Parr NJ,. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009; 104: 800-805
9. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-589
10. Kanis JA, Johansson H, Oden A, McCloskey EV,. Assessment of fracture risk. Eur J Radiol 2009; 71: 392-397
11. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-18
12. Anderson JR, Cain KC, Gelber RD,. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008; 26: 3913-3915
13. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456
14. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46
15. American Joint Committee on Cancer. Manual for Staging of Cancer, 5th edn. Philadelphia: JB Lippincott, 1997
16. Hamilton AS, Gloeckler Ries L,. Cancer of prostate. In, Ries L, Young J, Keel G, Eisner M, Lin YD, Horner M-J, eds, SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics, Chapt 22. Bethesda: National Cancer Institute, SEER Program, NIH Publication, 2007: 173-180
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
18. Albertsen PC, Walters S, Hanley JA,. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 2000; 163: 519-523
19. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR,. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513-521
20. Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380-390
21. Serpa Neto A, Tobias-Machado M, Esteves MA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36-44
22. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29